Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · HealthEquity (HQY)

HealthEquity Q1 revenue rises 15% to $330.8 million; net income up 87%

Positive Impact 4 of 5 earnings Written later

HealthEquity reported first-quarter results for the period ended April 30, 2025, with revenue of $330.8 million, up 15%, and GAAP net income of $53.9 million, or $0.61 per diluted share, up from $0.33 a year earlier. The company said it increased its full-year fiscal 2026 guidance, now calling for revenue of $1.285 billion to $1.305 billion and GAAP net income per diluted share of $1.96 to $2.13.

Key points

  • Revenue of $330.8 million, up 15% from $287.6 million a year earlier; Adjusted EBITDA of $140.2 million, up 19%
  • GAAP net income of $53.9 million, or $0.61 per diluted share, versus $28.8 million, or $0.33, in the prior-year quarter
  • Fiscal 2026 outlook: revenue $1.285 billion to $1.305 billion; Adjusted EBITDA $530 million to $550 million; non-GAAP net income per diluted share $3.61 to $3.78
  • Company repurchased 0.7 million shares for $60.3 million in the quarter; $117.5 million remained authorized as of April 30, 2025

The filing

CompanyHealthEquity (HQY)
Form8-K, current report
Filed with the SECJun 3, 2025, 4:03 PM ET
Accession number0001428336-25-000021

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:17 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 03, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.